Five-year study to examine how healthy brains age: ‘Research is urgently needed,’ says AES

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Natali_Mis)
(Image: Getty/Natali_Mis)

Related tags: Ppd, Accelerated Enrollment Solutions, Alzheimer's disease, Dementia, Clinical trials

PPD’s patient access business unit AES will support clinical trial enrollment of participants in the Synexus HealthyMinds Registry, which aims to register 30,000 adults for a five-year study.

Synexus HealthyMinds Registry (Synexus HMR) is a collaboration between the University of Exeter in the UK and Accelerated Enrollment Solutions (AES​), a business unit of the Wilmington, NC-based contract research organization (CRO) PPD​.  

The collaboration initially aims to register 30,000 adults aged 50 or older in the US without signs of dementia for a five-year study that will examine lifestyle and genetic risk factors affecting cognitive function.

To be conducted fully online, the study – now open – will include annual cognitive assessments, lifestyle and medical questionnaires, and free brain training games.

“Synexus HMR will provide valuable information about how the brain changes with age, investigate which combination of factors such as exercise and diet really work, and promote how to best encourage people to adopt these practices,”​ Dawie Wessels, MD, MBA, chief medical officer, Accelerated Enrollment Solutions (AES), told us.

Participants also may be presented with opportunities to join clinical trials, enrollment for which will be managed by AES and focused on areas surrounding Synexus sites and major Alzheimer’s research facilities, he explained.

Wessels said, “Research is urgently needed to identify potential methods of prevention and possible treatments for Alzheimer’s disease and other forms of dementia.”

Alzheimer’s is the sixth-leading cause of death in the US, and approximately 5.7 million Americans are currently living with the disease. This number is projected to grow to 14 million by 2050, according to the Alzheimer’s Association​.

Alzheimer’s and other dementias will cost the US $290bn this year – and up to $1.1tn by 2050.

Related news

Show more

Related products

show more

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Related suppliers

Follow us

Products

View more

Webinars